Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica (Q45832517)

16 December 2017

title

Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica (English)

1 reference

16 December 2017

1 reference

7

Susumu Kusunoki

1 reference

16 December 2017

Takashi Kageyama

1

1 reference

16 December 2017

Mika Komori

2

1 reference

16 December 2017

Katsuichi Miyamoto

3

1 reference

16 December 2017

Akihiko Ozaki

4

1 reference

16 December 2017

Toshihiko Suenaga

5

1 reference

16 December 2017

Ryosuke Takahashi

6

1 reference

16 December 2017

Sadayuki Matsumoto

8

1 reference

16 December 2017

Takayuki Kondo

9

1 reference

16 December 2017

publication date

18 October 2012

1 reference

16 December 2017

published in

Journal of Neurology

1 reference

16 December 2017

volume

260

1 reference

16 December 2017

issue

2

1 reference

16 December 2017

page(s)

627-634

1 reference

16 December 2017

https://scigraph.springernature.com/pub.10.1007/s00415-012-6692-2

exact match

0 references

cites work

The spectrum of neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Neuromyelitis optica treatment: analysis of 36 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Neuromyelitis optica: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Variable results after rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Revised diagnostic criteria for neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Effect of cyclosporine therapy with low doses of corticosteroids on idiopathic nephrotic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Monitoring treatment with cyclosporine microemulsion in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Intractable chronic inflammatory demyelinating polyneuropathy treated successfully with ciclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Relapsing transverse myelitis with anti-aquaporin 4 seropositivity: possible beneficial effects of ciclosporin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naïve T cells into cytokine-producing mature T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

Pathogenic T cell responses against aquaporin 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-012-6692-2

[Successful cyclosporine treatment in 2 patients with refractory CIDP, involving monitoring of both AUC(0-4h) and trough levels]

21 January 2018

1 reference

12 December 2020

Cyclosporine A in the long-term management of systemic lupus erythematosus

1 reference

12 December 2020

Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity

1 reference

12 December 2020

Immunoablative cyclophosphamide for refractory lupus-related neuromyelitis optica

1 reference

12 December 2020

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

1 reference

12 December 2020

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

1 reference

12 December 2020

Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation

1 reference

12 December 2020

Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients

1 reference

12 December 2020

10.1007/S00415-012-6692-2

Identifiers

DOI

1 reference

16 December 2017

Dimensions Publication ID

0 references

1 reference

16 December 2017